Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
gefitinib (iressa) (1 trial)
olaparib (lynparza) (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Lung Neoplasms (Phase 2)
Trials (1 total)
Trial APIs (2 total)